Iovance Biotherapeutics (IOVA) Tops Q2 EPS by 3c, misses on revenue

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q2 EPS of ($0.47), $0.03 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $3.91 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• UBS Reiterates Buy Rating on PVH Corp (PVH) on Strong Earnings Growth Potential
• Goldman Sachs sees bond markets as speed limiter for stocks